FDA Approves Sonrotoclax for R/R Mantle Cell Lymphoma

Oncology nurses have a new therapeutic option to manage in the treatment of relapsed or refractory mantle cell lymphoma (MCL) following the U.S. Food and Drug Administration (FDA) accelerated approval of sonrotoclax (Beqalzi). This next-generation BCL-2 inhibitor offers a necessary alternative for patients who have exhausted standard treatments, specifically requiring nursing vigilance during a mandatory 4-week dose ramp-up phase designed to mitigate the risk of tumor lysis syndrome (TLS).

The FDA indicated sonrotoclax for adult patients who have received at least two prior lines of systemic therapy, which must include a Bruton's tyrosine kinase (BTK) inhibitor. As MCL is a rare and aggressive malignancy accounting for approximately 5% of global non-Hodgkin lymphoma cases, this approval addresses a significant clinical gap for patients who frequently develop refractory disease.

Clinical trial outcomes

The accelerated approval was supported by data from the BGB-11417-201 trial, a multicenter, single-arm study of 103 adults. Key efficacy findings included:

• Overall Response Rate (ORR): 52%.
• Median Time to Response: 1.9 months.
• Median Duration of Response: 15.8 months.

Notably, sonrotoclax demonstrated efficacy in high-risk subgroups, including patients with the TP53 mutation, who achieved an ORR of 59.1%. Experts suggest that this agent could establish a foundational role in improving outcomes for those with limited remaining options after BTK therapy.

Nursing considerations and safety

Safety data from 115 patients revealed that serious adverse reactions occurred in 37% of participants. Pneumonia was the most frequent serious reaction, reported in 10% of the cohort.

Key safety monitoring priorities for the nursing team include:

• Tumor Lysis Syndrome: To reduce TLS risk, nurses must ensure patients adhere to the four-week ramp-up schedule before reaching the maintenance daily oral dose of 320 mg.
• Infection and Neutropenia: The drug’s prescribing information includes warnings for serious infections and neutropenia, necessitating regular hematologic monitoring.

The application for sonrotoclax received priority review and was processed under Project Orbis, an initiative allowing for concurrent review among international regulatory partners to expedite patient access to oncology products. Continued approval for this indication may depend on the verification of clinical benefit in subsequent confirmatory trials.

References

1. FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma. News release. U.S. Food and Drug Administration. May 13, 2024. Accessed May 13, 2026.
2. BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma. News release. BeOne Medicines USA, Inc. May 13, 2024. Accessed May 13, 2026.